Halflytely Patent Expiration

Halflytely is a drug owned by Braintree Laboratories Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 22, 2022. Details of Halflytely's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7291324 Method of bowel cleansing
Oct, 2022

(1 year, 11 months ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Halflytely's patents.

Given below is the list of recent legal activities going on the following patents of Halflytely.

Activity Date Patent Number
Patent litigations
Change in Power of Attorney (May Include Associate POA) 01 Jul, 2021 US7291324
Correspondence Address Change 30 Jun, 2021 US7291324
Payment of Maintenance Fee, 12th Yr, Small Entity 25 Apr, 2019 US7291324
Change in Power of Attorney (May Include Associate POA) 19 Nov, 2010 US7291324
Correspondence Address Change 16 Nov, 2010 US7291324
Post Issue Communication - Certificate of Correction 06 Feb, 2008 US7291324
Patent Issue Date Used in PTA Calculation 06 Nov, 2007 US7291324
Recordation of Patent Grant Mailed 06 Nov, 2007 US7291324
Email Notification 19 Oct, 2007 US7291324
Issue Notification Mailed 17 Oct, 2007 US7291324


FDA has granted several exclusivities to Halflytely. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Halflytely, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Halflytely.

Exclusivity Information

Halflytely holds 1 exclusivities. All of its exclusivities have expired in 2013. Details of Halflytely's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 16, 2013

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Halflytely is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Halflytely's family patents as well as insights into ongoing legal events on those patents.

Halflytely's Family Patents

Halflytely has patent protection in a total of 1 countries. It has a significant patent presence in the US with 100.0% of its patents being US patents. Click below to unlock the full patent family tree for Halflytely.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Halflytely's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 22, 2022 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Halflytely Generics:

Bisacodyl; Polyethylene Glycol 3350; Potassium Chloride; Sodium Bicarbonate; Sodium Chloride is the generic name for the brand Halflytely. 1 company has already filed for the generic of Halflytely. Check out the entire list of companies who have already received approval for Halflytely's generic

Alternative Brands for Halflytely

Halflytely which is used for cleansing the colon before a colonoscopy in adults., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Braintree Labs
Suprep Bowel Prep Kit Used for cleansing the colon as preparation for colonoscopy in adults.





About Halflytely

Halflytely is a drug owned by Braintree Laboratories Inc. It is used for cleansing the colon before a colonoscopy in adults. Halflytely uses Bisacodyl; Polyethylene Glycol 3350; Potassium Chloride; Sodium Bicarbonate; Sodium Chloride as an active ingredient. Halflytely was launched by Braintree in 2007.

Approval Date:

Halflytely was approved by FDA for market use on 24 September, 2007.

Active Ingredient:

Halflytely uses Bisacodyl; Polyethylene Glycol 3350; Potassium Chloride; Sodium Bicarbonate; Sodium Chloride as the active ingredient. Check out other Drugs and Companies using Bisacodyl; Polyethylene Glycol 3350; Potassium Chloride; Sodium Bicarbonate; Sodium Chloride ingredient

Treatment:

Halflytely is used for cleansing the colon before a colonoscopy in adults.

Dosage:

Halflytely is available in the following dosage forms - tablet, delayed release, for solution form for oral use, for solution, tablet, delayed release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** FOR SOLUTION, TABLET, DELAYED RELEASE Discontinued ORAL
5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM TABLET, DELAYED RELEASE, FOR SOLUTION Discontinued ORAL